Patients facing higher out-of-pocket costs predicted procedures would hurt more than procedures with no copay, according to the results of a recent Carnegie Mellon study.
Out-of-pocket costs may affect more than patients’ wallets, raising anticipated pain and discouraging some from scheduling care, according to a new study out of Carnegie Mellon University.
The FDA cleared Teva’s Igalmi sublingual film for at-home use, the first at-home approved option for agitation tied to schizophrenia or bipolar disorder.
Drug launch prices are rising, but Benjamin N. Rome, M.D., M.P.H., and colleagues found no evidence manufacturers raised them in response to the Inflation Reduction Act.
What would it mean to treat vision, hearing and dental utilization as population health metrics, the same way we track vaccination rates or chronic disease management gaps?